Rigel Pharmaceuticals, Inc. (RIGL) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin 124.7%, revenue growth 64.1% YoY, P/E 13.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $294.28M |
| Revenue (TTM) | $0.3B |
| Net Margin | 124.7% |
| Operating Margin (TTM) | 30.5% |
| Net Debt / EBITDA | 0.2 |
| Revenue Growth (YoY) | 64.1% |
| EPS Growth (YoY) | 1960.6% |
| P/E Ratio | 13.7 |
| EV / EBITDA | 9.9 |
| Price / Book | 2.01 |
| Price / Sales | 3.23 |
| Altman Z-Score | 3.09 (safe) |
| Piotroski F-Score | 6/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
RIGL overview · RIGL earnings · RIGL KPIs · RIGL documents · RIGL ownership · RIGL peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.